U.S. regulators are expediting the review of biotech seeds after a "bit of uncertainty" resulted in a delay in the approval process, said Paul Schickler, president of DuPont's Pioneer Hi-Bred International unit. The company bolstered its resources for regulatory affairs in an effort to commercialize six biotech traits between this year and 2013, Schickler said.

Full Story:

Related Summaries